Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
-
US consumer confidence tumbles in December
-
Norwegian biathlete Sivert Guttorm Bakken found dead in hotel
-
UK comedian Russell Brand faces two new rape, assault charges: police
-
Venezuela seeks to jail backers of US oil blockade
-
Norwegian biathlete Sivert Guttorm Bakken found dead
-
Wall Street stocks edge higher
-
Vietnam Communist Party endorses To Lam to stay in top job
-
US economic growth surges in 3rd quarter, highest rate in two years
-
Frank defends Van de Ven after Slot slams 'reckless' foul on Isak
-
Russian paramilitaries in CAR say take election threat 'extremely seriously'
-
Trump in the Epstein files: five takeaways from latest release
-
UK govt to relax farmers inheritance tax after protests
-
Pakistani firm wins auction for state airline PIA
-
Stocks slip on strong US growth data
-
DR Congo beat Benin to kick off Cup of Nations bid
-
New Epstein files dump contains multiple Trump references
-
Russian strike could collapse Chernobyl shelter: plant director
-
Springbok captain Kolisi to rejoin Stormers
-
Italy fines Ryanair $300 mn for abuse of dominant position
-
Mahrez eyes strong AFCON showing from Algeria
-
Killer in Croatia school attack gets maximum 50-year sentence
-
Thousands of new Epstein-linked documents released by US Justice Dept
-
Stocks steady as rate cut hopes bring Christmas cheer
-
Bangladesh summons Indian envoy as protest erupts in New Delhi
-
Liverpool's Isak faces two months out after 'reckless' tackle: Slot
-
For director Josh Safdie, 'Marty Supreme' and Timothee Chalamet are one and the same
-
Kyiv's wartime Christmas showcases city's 'split' reality
-
Locals sound alarm as Bijagos Islands slowly swallowed by sea
-
Cambodia asks Thailand to move border talks to Malaysia
-
In Bulgaria, villagers fret about euro introduction
-
Key to probe England's 'stag-do' drinking on Ashes beach break
-
Delayed US data expected to show solid growth in 3rd quarter
-
Thunder bounce back to down Grizzlies, Nuggets sink Jazz
-
Amazon says blocked 1,800 North Koreans from applying for jobs
-
Trump says US needs Greenland 'for national security'
-
Purdy first 49er since Montana to throw five TDs as Colts beaten
-
North Korea's Kim tours hot tubs, BBQ joints at lavish new mountain resort
-
Asian markets rally again as rate cut hopes bring Christmas cheer
-
Australian state poised to approve sweeping new gun laws, protest ban
-
Trapped under Israeli bombardment, Gazans fear the 'new border'
-
Families want answers a year after South Korea's deadliest plane crash
-
Myanmar's long march of military rule
-
Disputed Myanmar election wins China's vote of confidence
-
Myanmar junta stages election after five years of civil war
-
Ozempic Meals? Restaurants shrink portions to match bite-sized hunger
-
'Help me, I'm dying': inside Ecuador's TB-ridden gang-plagued prisons
-
Australia's Cummins, Lyon out of fourth Ashes Test
-
US singer Barry Manilow reveals lung cancer diagnosis
-
'Call of Duty' co-creator Vince Zampella killed in car crash
-
Investor Tools Highlighted by BNK Invest
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| CMSC | 0.01% | 23.1399 | $ | |
| BCC | -1.28% | 73.29 | $ | |
| AZN | 0.47% | 91.985 | $ | |
| BCE | -0.11% | 22.705 | $ | |
| RIO | 1.15% | 81.03 | $ | |
| NGG | 1.09% | 77.255 | $ | |
| BTI | 0.36% | 56.975 | $ | |
| CMSD | -0.78% | 23.02 | $ | |
| GSK | 0.3% | 48.735 | $ | |
| JRI | 0.37% | 13.42 | $ | |
| BP | 1.16% | 34.541 | $ | |
| RBGPF | 0% | 80.22 | $ | |
| RELX | -0.09% | 40.945 | $ | |
| VOD | 1.23% | 13.04 | $ | |
| RYCEF | 0.19% | 15.53 | $ |
Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
- Video webcast now available on-demand
AURORA, CO / ACCESS Newswire / July 22, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced Soren Mogelsvang PhD, President and Chief Executive Officer and Founder of Exxel, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
As part of the event, Dr. Mogelsvang dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Company's website (exxelpharma.com).
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company's lead program, EX937, is a novel, oral, patented small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel plans to launch a first-in-human Phase 1/1b study of EX937 for the treatment of refractory chronic cough, a large underserved market with no current FDA-approved therapies. In preclinical studies, EX937 demonstrated efficacy in its ability to modulate chronic cough in multiple models. Additionally, EX937 has shown to have a favorable preclinical safety profile and is expected to have no CNS side effects by being entirely excluded from the central nervous system and brain. EX937 also has the potential to be utilized across a number of high-value indications, including hyperactive bladder, peripheral neuropathic pain and migraine headaches. Exxel Pharma has a second program (ARN compounds) with the potential to treat Social Anxiety and Autism Spectrum Disorder.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
E: [email protected]
SOURCE: Exxel Pharma, Inc.
View the original press release on ACCESS Newswire
P.Silva--AMWN